Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452472 | 0.92 | HDAC1 (0.62) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL450147 | 0.89 | HDAC1 (0.58) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL449673 | 0.87 | HDAC1 (0.58) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL450609 | 0.86 | HDAC1 (0.57) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL447359 | 0.85 | HDAC1 (0.56) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL451070 | 0.83 | HDAC1 (0.64) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL2418799 | 0.79 | HDAC1 (0.77) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL2413774 | 0.78 | PTGS1 (0.78) | HDAC1HDAC2HDAC3HDAC8HDAC6 | |
| SCHEMBL447230 | 0.77 | HDAC1 (0.54) | HDAC1HDAC2BRD4HDAC3PTGS1 | |
| SCHEMBL1062997 | 0.74 | HDAC1 (0.94) | HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716326-B2 | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-05-06 | — | — | US | claimed |
| EP-2429987-A2 | AMIDE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Research Institute Of Chemical Technology (KR) | 2012-03-21 | — | — | EP | claimed |
| US-20120065396-A1 | ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-03-15 | — | — | US | claimed |
| WO-2010131922-A2 | AMIDE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-11-18 | — | — | WO | claimed |
| US-8716326-B2 | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-05-06 | — | — | US | disclosed |
| EP-2429987-A2 | AMIDE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Research Institute Of Chemical Technology (KR) | 2012-03-21 | — | — | EP | disclosed |
| US-20120065396-A1 | ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-03-15 | — | — | US | disclosed |
| WO-2010131922-A2 | AMIDE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065396-A1 | ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME | PPIP5K2, SOST, ALPL | HDAC1 761/4885HDAC2 641/4885BRD4 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.